IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans
Adam Steensberg,1,2
Christian P. Fischer,1,2
Charlotte Keller,1,2
Kirsten Møller,2 and
Bente Klarlund Pedersen1,2
1The Copenhagen Muscle Research Centre and
2The Department of Infectious Diseases,
Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
Submitted 19 February 2003
; accepted in final form 20 April 2003
 |
ABSTRACT
|
---|
The purpose of the present study was to test the hypothesis that a
transient increase in plasma IL-6 induces an anti-inflammatory environment in
humans. Therefore, young healthy volunteers received a low dose of recombinant
human (rh)IL-6 or saline for 3 h. Plasma IL-6 levels during rhIL-6 infusion
were
140 pg/ml, corresponding to the levels obtained during strenuous
exercise. The infusion of rhIL-6 did not induce enhanced levels of the
proinflammatory cytokine TNF-
but enhanced the plasma levels of the two
anti-inflammatory cytokines IL-1 receptor agonist (IL-1ra) and IL-10 compared
with saline infusion. In addition, C-reactive protein increased 3 h
post-rhIL-6 infusion and was further elevated 16 h later compared with saline
infusion. rhIL-6 induced increased levels of plasma cortisol and,
consequently, an increase in circulating neutrophils and a decrease in the
lymphocyte number without effects on plasma epinephrine, body temperature,
mean arterial pressure, or heart rate. In conclusion, this study demonstrates
that physiological concentrations of IL-6 induce an anti-inflammatory rather
than an inflammatory response in humans and that IL-6, independently of
TNF-
, enhances the levels not only of IL-1ra but also of IL-10.
Furthermore, IL-6 induces an increase in cortisol and, consequently, in
neutrocytosis and late lymphopenia to the same magnitude and with the same
kinetics as during exercise, suggesting that muscle-derived IL-6 has a central
role in exercise-induced leukocyte trafficking.
cytokines; C-reactive protein; tumor necrosis factor-
; neutrophils and lymphocytes; interleukin-1 receptor agonist
INTERLEUKIN (IL)-6 has initially been classified as a
proinflammatory cytokine, mainly because it increases in the early course of
an infection. However, it was recently suggested that IL-6 should be
classified as an anti-inflammatory cytokine
(32). In vitro studies
(9), as well as animal studies
(16,
18), suggest that IL-6
inhibits TNF-
production. Studies in IL-6 knockout mice have
demonstrated that these mice possess a compromised ability to control the
proinflammatory cytokine response to injected endotoxin
(35). Recently, we
demonstrated that infusion of recombinant human (rh)IL-6 to healthy volunteers
inhibited low-grade endotoxin-induced TNF-
production
(25a). A number of
epidemiological studies have shown increased levels of both TNF-
and
IL-6 in aging (4), in obese
individuals (2), and in
patients with type 2 diabetes
(13,
17,
24,
34). Furthermore, plasma
concentrations of IL-6 have been shown to predict total and cardiovascular
mortality in population-based studies
(25). It is, however, not
known whether chronically elevated levels of IL-6 are causally related to
atherosclerosis, obesity, and insulin resistance. On the basis of evidence
that IL-6 exerts anti-inflammatory effects, it is likely that the elevated
plasma IL-6 found in these individuals represents low-grade inflammation,
rather than its cause.
We have used exercise as a model for the study of metabolic and
immunological interactions (for reviews see Refs.
22 and
23). During strenuous
exercise, several cytokines transiently increase in plasma along with changes
in circulating immune cells
(21). The increase in IL-6
during exercise precedes that of other cytokines examined
(20). Therefore, IL-6 is
likely to play a central role in the cytokine cascade. The IL-6 gene is
expressed within and released from contracting muscles
(30), especially when
intramuscular glycogen is low
(14,
26). There is evidence to
suggest that one function of muscle-derived IL-6 during exercise is to work as
a hormone by increasing substrate mobilization
(15). In addition,
muscle-derived IL-6 may also induce anti-inflammatory effects. High plasma
concentrations of IL-6 induce the expression of the IL-1 receptor antagonist
(ra) (33), a cytokine that
antagonizes the effects of the proinflammatory cytokine IL-1
(8). Whether IL-6,
independently of TNF-
, induces IL-10, one of the other major
anti-inflammatory cytokines, is not known. Injection of IL-6 into humans
increases plasma adrenocorticotropic hormone and plasma cortisol
(3,
31). Moreover, both the
pituitary corticotrophs and adrenocortical cells express IL-6 receptors, and
IL-6 is able to induce an increase in cortisol both directly and indirectly
(3).
Acute elevations in plasma IL-6 either by infusion of IL-6 or by exercise
are therefore likely to stimulate the anti-inflammatory environment, thereby
reducing any ongoing inflammatory processes in the host. These same subjects,
however, might consequently also experience immune impairment and enhanced
susceptibility to infections.
Exercise induces highly stereotyped changes in leukocyte subpopulations.
Thus the number of neutrophils increases during and after exercise, whereas
the lymphocyte number increases during exercise and decreases in the
postexercise period (22).
Whereas the initial changes can be ascribed to the effect of catecholamines
(29), the prolonged changes in
leukocyte numbers are most likely mediated through an effect of muscle-derived
IL-6 on cortisol production.
In the present study, a low dose of rhIL-6 or saline was infused for 3 h
into healthy humans. The plasma IL-6 levels obtained were comparable to those
observed during strenuous prolonged exercise
(21). Any changes in cortisol,
lymphocytes, neutrophils, C-reactive protein (CRP), IL-10, IL-1ra, and
TNF-
were measured in the blood during the infusion and in the hours
after it. We hypothesized that IL-6 infusion would induce an increase in
plasma IL-1ra and IL-10, plasma CRP, and cortisol as well as a consequent
increase in neutrophil and decrease in lymphocyte numbers, without any changes
in TNF-
.
 |
METHODS
|
---|
Subjects. Twelve healthy, active, but not specifically trained
males participated in the study. The subjects were divided into two groups,
receiving either saline or rhIL-6 infusion. The mean (±SE) ages of the
two groups were 23 ± 1 and 24 ± 1 yr, without any significant
differences. The study was approved by the Ethical Committee of Copenhagen and
Frederiksberg Communities, Denmark, and was performed according to the
Declaration of Helsinki. Subjects were informed about the possible risks and
discomfort involved before giving their written consent to participate.
Protocol. Subjects reported to the laboratory at 0700 after an
overnight fast. They voided, changed into appropriate hospital attire, and
remained supine during the entire experiment. They were permitted to consume
only water during the experiment. After 10 min, the femoral arteries of both
legs were cannulated as previously described
(26). One femoral arterial
catheter was used for the infusion of rhIL-6 or saline. The other arterial
line was used for blood sampling. At
1000, the 3-h infusion of rhIL-6 or
saline commenced.
IL-6 infusates. The rhIL-6 (Sandoz, Basel, Switzerland) was
infused in a dose lower than that reported to be safe in other studies
(31). The IL-6 doses were
chosen on the basis of pilot experiments. We aimed to reach plasma levels of
IL-6 characteristic of intense exercise or low-grade inflammation. The rate of
rhIL-6 infusion was 30 µg/h, with saline used as a vehicle. Saline was
infused during the control trial.
Blood analysis. Blood samples for IL-6, IL-10, IL-1ra, and
TNF-
were measured by high-sensitivity ELISA, as previously described
(21), and CRP, blood
lymphocytes, and neutrophils were measured by standard laboratory procedures.
Plasma epinephrine was measured by HPLC, and plasma cortisol (Diagnostic
Products, Los Angeles, CA) was analyzed by radioimmunoassay, as previously
described (27).
Physiological variables. Heart rate and mean arterial pressure
(MAP) were measured every 60 min by use of electrocardiography and
sphygmomanometry, respectively. Temperature was also measured at these time
points via a tympanic probe.
Statistics. All data are presented as means ± SE;
n = 6. Plasma IL-6, IL-1ra, IL-10, and TNF-
values were log
transformed to obtain a normal distribution. To analyze changes over time and
between groups, a two-way repeated-measures analysis of variance (RM-ANOVA)
was used. If such analysis revealed significant differences, a Newman-Keuls
post hoc test was used to locate the specific differences. P <
0.05 was accepted as significant.
 |
RESULTS
|
---|
At steady state during saline and rhIL-6 infusions, plasma IL-6
concentrations were
4 and 140 pg/ml, respectively. At the cessation of
the rhIL-6 infusion, plasma IL-6 declined rapidly toward preinfusion levels
within the first hour. Plasma epinephrine, heart rate, MAP, and temperature
were not affected by IL-6 infusion or time, as shown in
Table 1.
View this table:
[in this window]
[in a new window]
|
Table 1. Plasma IL-6, plasma epinephrine, temperature, MAP, and heart rate
before, during, and after saline or low-dose rhIL-6 infusion
|
|
Infusion of rhIL-6 did not affect the levels of TNF-
in the plasma
(Fig. 1A). The two
cytokines IL-10 and IL-1ra significantly increased (P < 0.05)
during the rhIL-6 infusion compared with saline and preinfusion, with
8-fold and
26-fold increases, respectively. At the cessation of the
infusion, the plasma concentrations of both cytokines declined toward basal
levels (Fig. 1, B and
C). Plasma CRP was increased (P < 0.05) 3 h
after the cessation of the rhIL-6 infusion, reaching 22 ± 3 mg/l 16 h
later (Fig. 2).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1. Plasma TNF- (A), plasma IL-10 (B), and IL-1
receptor agonist (IL-1ra, C) before, during, and after 3-h infusion
of either saline or a low dose of recombinant human (rh)IL-6. Values are means
± SE; n = 6. P < 0.05: *difference from
preinfusion; #difference from saline infusion.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 2. Plasma C-reactive protein (CRP) before, during, and after 3-h infusion of
either saline or a low dose of rhIL-6. Values are means ± SE;
n = 6. P < 0.05: *difference from preinfusion;
#difference from saline infusion.
|
|
Plasma cortisol increased (P < 0.05) during rhIL-6 infusion and
declined toward basic levels at the cessation of infusion
(Fig. 3A). The number
of circulating neutrophils increased (P < 0.05) during the rhIL-6
infusion, peaking 2 h into the infusion (13.1 ± 0.8 x
109/l) compared with control (5.5 ± 0.7 x
109/l). The next day, circulating neutrophils were back to
preinfusion numbers (Fig.
3B). The lymphocyte number declined modestly (P
< 0.05) during the rhIL-6 infusion but did not change during saline
infusion (Fig.
3C).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3. Plasma cortisol (A), circulating neutrophils (B), and
lymphocytes (C) before, during, and after 3-h infusion of either
saline or a low dose of rhIL-6. Values are means ± SE; n = 6.
P < 0.05: *difference from preinfusion; #difference
from saline infusion.
|
|
 |
DISCUSSION
|
---|
The findings from the present study support the hypothesis that IL-6 is an
anti-inflammatory cytokine. This is suggested by its very high plasma
concentrations observed during infections and by its release from contracting
skeletal muscle during exercise. In this study, we show that an acute
experimental elevation of plasma IL-6 induced a transient increase in the
plasma levels of the two anti-inflammatory cytokines IL-1ra and IL-10 and
cortisol and caused a delayed increase in plasma CRP. This took place without
any effect on the levels of plasma TNF-
, plasma catecholamines,
temperature, MAP, or heart rate, thus indicating that an important function of
IL-6 is to limit the potentially injurious effects of sustained
inflammation.
IL-6 is known to inhibit an endotoxin-associated increase in TNF-
in
humans (25a). Because we found
that IL-6 infusion did not decrease the basal plasma levels of TNF-
, it
is possible that IL-6 influences circulating levels of TNF-
by
inhibiting dynamic TNF-
production or release. However, we cannot
exclude the possibility that treatment with IL-6 for days would have an effect
on the basal plasma levels of TNF-
, especially in individuals who have
higher basal plasma levels of TNF-
, such as aged or obese subjects or
patients with type 2 diabetes.
To our knowledge, this is the first study to demonstrate that IL-6,
independently of TNF-
, induces the release of IL-10. Others have
demonstrated that supraphysiological doses of IL-6 concentrations induce
IL-1ra in humans (33). The
only known biological role of IL-1ra is its ability to bind to the IL-1
receptor and thereby inhibit the function(s) of IL-1
and IL-1
(8). IL-1ra is mainly produced
by monocytes and macrophages after stimulation with lipopolysaccharide
(8) or the cytokines IL-4,
IL-6, IL-10, and IL-14 (7).
IL-10 is produced by Th2 lymphocytes, monocytes, and B cells, and it inhibits
several immune pathways. Moreover, IL-10 is a potent inhibitor of Th1-,
monocyte-, and macrophage-derived cytokines
(19). In addition, IL-10
attenuates the surface expression of TNF-
receptors
(6,
12). The finding that plasma
CRP was higher 16 h postinfusion than after 3 h demonstrates a prolonged
anti-inflammatory effect of the rhIL-6 infusion. CRP and other acute-phase
proteins are anti-inflammatory and immunosuppressive mediators
(32). Moreover, in in vivo
models, CRP can inhibit polymorphonuclear (PMN) leukocyte infiltration
(11) and attenuate vascular
injury induced by stimulated PMN leukocytes
(1). In an in vitro model
(10), CRP inhibits
intracellular calcium mobilization and superoxide production by alveolar
macrophages.
The IL-6-induced increase in plasma cortisol is in agreement with previous
findings (3,
31); therefore, the increase
in circulating neutrophils found in this study is likely to be caused by the
increase in plasma cortisol. Cortisol increases the circulating pool of
neutrophils by inhibiting their ability to bind to the endothelial membrane
(5) and to infiltrate into the
tissue. Hence, the increased neutrophil number during rhIL-6 infusion is a
sign of anti-inflammatory cortisol action. Exercise increases circulating
neutrophils to a similar extent
(29). It is therefore likely
that muscle-derived IL-6 mediates this effect. A small decrease in the
circulating pool of lymphocytes toward the end of rhIL-6 infusion supports the
observation that the late lymphopenia seen during the recovery from exercise
(29) may also be caused by
IL-6. Exercise-induced disappearance of type 1 cytokine-producing cells from
the circulation (28) may be
related to elevated levels of IL-10. Also, the plasma IL-1ra and IL-10
increases seen during exercise
(21) are likely to be mediated
by IL-6.
In conclusion, this study demonstrates that physiological concentrations of
IL-6 induce an anti-inflammatory rather than a proinflammatory response in
humans and that IL-6, independently of TNF-
, enhances the levels not
only of IL-1ra but also of IL-10. Furthermore, IL-6 stimulates cortisol
release and thus produces neutrocytosis and lymphopenia of the same magnitude
and pattern as are seen during intense exercise. This suggests that
muscle-derived IL-6, in addition to its metabolic effects, plays a key role in
exercise-induced leukocyte trafficking.
 |
DISCLOSURES
|
---|
This study was supported by the Danish National Research Foundation
(50414) and by a grant from the Medical Faculty of Copenhagen
University.
 |
ACKNOWLEDGMENTS
|
---|
We thank Ruth Rousing and Hanne Villumsen for excellent technical
assistance.
 |
FOOTNOTES
|
---|
Address for reprint requests and other correspondence: A. Steensberg, The
Copenhagen Muscle Research Centre, Rigshospitalet 7641, Blegdamsvej 9, DK-2100
Copenhagen, Denmark (E-mail:
SBERG{at}rh.dk).
Submitted 19 February 2003
The costs of publication of this article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
 |
REFERENCES
|
---|
- Abernathy VJ,
Webster RO, and Dahms TE. C-reactive protein inhibits increased pulmonary
vascular permeability induced by fMLP in isolated rabbit lungs. Am
J Physiol Heart Circ Physiol 271:
H507H513, 1996.[Abstract/Free Full Text]
- Bastard JP,
Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, and Hainque
B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous
adipose tissue of obese women after weight loss. J Clin Endocrinol
Metab 85:
33383342, 2000.[Abstract/Free Full Text]
- Bethin KE, Vogt
SK, and Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing
hormone-independent stimulator of the adrenal axis during immune system
activation. Proc Natl Acad Sci USA
97: 93179322,
2000.[Abstract/Free Full Text]
- Bruunsgaard H,
Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, and Pedersen BK. A
high plasma concentration of TNF-alpha is associated with dementia in
centenarians. J Gerontol A Biol Sci Med Sci
54: M357M364,
1999.[ISI][Medline]
- Cronstein BN,
Kimmel SC, Levin RI, Martiniuk F, and Weissmann G. A mechanism for the
antiinflammatory effects of corticosteroids: the glucocorticoid receptor
regulates leukocyte adhesion to endothelial cells and expression of
endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule
1. Proc Natl Acad Sci USA 89:
99919995, 1992.[Abstract]
- Dickensheets HL, Freeman SL, Smith MF, and Donnelly RP.
Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene
expression in endotoxin-stimulated human monocytes.
Blood 90:
41624171, 1997.[Abstract/Free Full Text]
- Dinarello CA. Induction of interleukin-1 and interleukin-1
receptor antagonist. Semin Oncol
24: S9,
1997.[ISI]
- Dinarello CA. Interleukin-1, interleukin-1 receptors and
interleukin-1 receptor antagonist. Int Rev Immunol
16: 457499,
1998.[Medline]
- Fiers W.
Tumor necrosis factor. Characterization at the molecular, cellular and in vivo
level. FEBS Lett 285:
199212, 1991.[ISI][Medline]
- Foldes-Filep E,
Filep JG, and Sirois P. C-reactive protein inhibits intracellular calcium
mobilization and superoxide production by guinea pig alveolar macrophages.
J Leukoc Biol 51:
1318, 1992.[Abstract]
- Heuertz RM,
Piquette CA, and Webster RO. Rabbits with elevated serum C-reactive
protein exhibit diminished neutrophil infiltration and vascular permeability
in C5a-induced alveolitis. Am J Pathol
142: 319328,
1993.[Abstract]
- Joyce DA,
Gibbons DP, Green P, Steer JH, Feldmann M, and Brennan FM. Two inhibitors
of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have
contrasting effects on release of soluble p75 tumor necrosis factor receptor
by cultured monocytes. Eur J Immunol
24: 26992705,
1994.[ISI][Medline]
- Katsuki A,
Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K,
Goto H, Nakatani K, and Yano Y. Serum levels of tumor necrosis
factor-alpha are increased in obese patients with noninsulin-dependent
diabetes mellitus. J Clin Endocrinol Metab
83: 859862,
1998.[Abstract/Free Full Text]
- Keller C,
Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, and Neufer PD.
Transcriptional activation of the IL-6 gene in human contracting skeletal
muscle: influence of muscle glycogen content. FASEB J
15: 27482750,
2001.[Abstract/Free Full Text]
- Lyngso D,
Simonsen L, and Bulow J. Metabolic effects of interleukin-6 in human
splanchnic and adipose tissue. J Physiol
543: 379386,
2002.[Abstract/Free Full Text]
- Matthys P,
Mitera T, Heremans H, Van Damme J, and Billiau A. Anti-gamma interferon
and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced
weight loss, hypoglycemia, and cytokine release in
D-galactosamine-sensitized and unsensitized mice. Infect
Immun 63:
11581164, 1995.[Abstract]
- Mishima Y,
Kuyama A, Tada A, Takahashi K, Ishioka T, and Kibata M. Relationship
between serum tumor necrosis factor-alpha and insulin resistance in obese men
with type 2 diabetes mellitus. Diabetes Res Clin Pract
52: 119123,
2001.[ISI][Medline]
- Mizuhara H,
O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H,
and Fujiwara H. T cell activation-associated hepatic injury: mediation by
tumor necrosis factors and protection by interleukin 6. J Exp
Med 179:
15291537, 1994.[Abstract]
- Opal SM and
DePalo VA. Anti-inflammatory cytokines. Chest
117: 11621172,
2000.[Abstract/Free Full Text]
- Ostrowski K,
Hermann C, Bangash A, Schjerling P, Nielsen JN, and Pedersen BK. A
trauma-like elevation of plasma cytokines in humans in response to treadmill
running. J Physiol 513:
889894, 1998.[Abstract/Free Full Text]
- Ostrowski K,
Rohde T, Asp S, Schjerling P, and Pedersen BK. Pro- and anti-inflammatory
cytokine balance in strenuous exercise in humans. J
Physiol 515:
287291, 1999.[Abstract/Free Full Text]
- Pedersen BK and
Hoffman-Goetz L. Exercise and the immune system: regulation, integration,
and adaptation. Physiol Rev 80:
10551081, 2000.[Abstract/Free Full Text]
- Pedersen BK,
Steensberg A, and Schjerling P. Muscle-derived interleukin-6: possible
biological effects. J Physiol
536: 329337,
2001.[Abstract/Free Full Text]
- Pickup JC,
Chusney GD, Thomas SM, and Burt D. Plasma interleukin-6, tumour necrosis
factor alpha and blood cytokine production in type 2 diabetes. Life
Sci 67:
291300, 2000.[ISI][Medline]
- Ridker PM,
Rifai N, Stampfer MJ, and Hennekens CH. Plasma concentration of
interleukin-6 and the risk of future myocardial infarction among apparently
healthy men. Circulation 17,
2000.
- Starkie R,
Ostrowski SR, Jauffred S, Febbraio M, and Pedersen BK. Exercise and IL-6
infusion inhibit endotoxin-induced TNF-
production in humans.
FASEB J 17:
884886, 2003.[Abstract/Free Full Text]
- Steensberg A,
Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B, and Pedersen BK.
Interleukin-6 production in contracting human skeletal muscle is influenced by
pre-exercise muscle glycogen content. J Physiol
537: 633639,
2001.[Abstract/Free Full Text]
- Steensberg A,
Morrow J, Toft D, Bruunsgaard H, and Pedersen BK. Prolonged exercise,
lymphocyte apoptosis and F2-isoprostanes. Eur J Appl
Physiol 87:
3842, 2002.[ISI][Medline]
- Steensberg A,
Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, and Pedersen
BK. Strenuous exercise decreases the percentage of type 1 T cells in the
circulation. J Appl Physiol 91:
17081712, 2001.[Abstract/Free Full Text]
- Steensberg A,
Toft AD, Schjerling P, Halkjaer-Kristensen J, and Pedersen BK. Plasma
interleukin-6 during strenuous exercise: role of epinephrine. Am J
Physiol Cell Physiol 281:
C1001C1004, 2001.[Abstract/Free Full Text]
- Steensberg A,
van Hall G, Osada T, Sacchetti M, Saltin B, and Pedersen BK. Production of
interleukin-6 in contracting human skeletal muscles can account for the
exercise-induced increase in plasma interleukin-6. J
Physiol 529:
237242, 2000.[Abstract/Free Full Text]
- Stouthard JM,
Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, and
Sauerwein HP. Endocrino-logic and metabolic effects of interleukin-6 in
humans. Am J Physiol Endocrinol Metab
268: E813E819,
1995.[Abstract/Free Full Text]
- Tilg H,
Dinarello CA, and Mier JW. IL-6 and APPs: anti-inflammatory and
immunosuppressive mediators. Immunol Today
18: 428432,
1997.[ISI][Medline]
- Tilg H, Trehu
E, Atkins MB, Dinarello CA, and Mier JW. Interleukin-6 (IL-6) as an
anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist
and soluble tumor necrosis factor receptor p55. Blood
83: 113118,
1994.[Abstract/Free Full Text]
- Vozarova B,
Weyer C, Hanson K, Tataranni PA, Bogardus C, and Pratley RE. Circulating
interleukin-6 in relation to adiposity, insulin action, and insulin secretion.
Obes Res 9:
414417, 2001.[Abstract/Free Full Text]
- Xing Z, Gauldie
J, Cox G, Baumann H, Jordana M, Lei XF, and Achong MK. IL-6 is an
antiinflammatory cytokine required for controlling local or systemic acute
inflammatory responses. J Clin Invest
101: 311320,
1998.[Abstract/Free Full Text]